Saroja Pharma

India Founded: 2019 • Age: 7 yrs Listed
Specialty chemical trader, exporter, and supplier that offers a range of products, with a focus on pharmaceutical ingredients

About Saroja Pharma

Saroja Pharma is a publicly listed company based in India founded in 2019. Specialty chemical trader, exporter, and supplier that offers a range of products, with a focus on pharmaceutical ingredients. Its Indian entity Saroja Pharma Industries India Limited reported revenue of β‚Ή70.24 Cr. Saroja Pharma offers products and services including Specialty Chemicals, Pharma API, and Pharma Intermediates. Its focus areas include Pharmaceutical Distributors and Active Pharmaceutical Ingredients. Its competitors include Del Trade, Globofarm International and HUFORT HEALTHCARE.

Company details

Saroja Pharma Industries India Ltd was founded in 2019 in India. Specialty chemicals, including pharmaceutical ingredients, are traded, exported, and supplied by the company. A range of products is provided to meet industry needs. Operations emphasize ethical practices, equal opportunity, and a harassment-free workplace. Corporate governance is upheld through transparency and accountability in all dealings.

  • Headquarters India
  • Stage Public
  • Sectors
    Healthcare
  • Website sarojapharma.com
  • Legal Name Saroja Pharma Industries India Ltd.
Key Metrics
  • Market Cap
    ₹14.51 Cr

    SAROJA-SM · NSE

  • Share Price
    ₹34.30

    -4.99% today

  • Revenue
    ₹70.13 Cr

    FY 2025-26 · +30.5% YoY

  • EBITDA
    ₹3.73 Cr

    Margin 5.3%

  • Net Profit
    ₹1.68 Cr

    FY 2025-26 · +61.5% YoY

  • P/E (TTM)
    9.1x

    P/B 0.9x

  • ROE
    9.8%

    ROCE 13.1%

  • Debt / Equity
    0.72

    Interest cover 41.2x

Products & Services of Saroja Pharma

Saroja Pharma offers a comprehensive portfolio of products and services, including Specialty Chemicals, Pharma API, and Pharma Intermediates.

Specialty Chemicals
Chemical Supply

Trading and supplying effective specialty chemicals for various industries.

Pharma API
Pharmaceuticals

Active ingredients for drug manufacturing and export.

Pharma Intermediates
Pharmaceuticals

Intermediate compounds used in pharma production processes.

Board of directors of Saroja Pharma Industries India Limited (Saroja Pharma)

Saroja Pharma Industries India Limited is the primary company behind Saroja Pharma. The board of Saroja Pharma Industries India Limited currently have 8 directors; the longest-serving is Biju Gopinathan Nair, appointed in 2019. 8 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Biju Gopinathan Nair
DIN 08330223
Managing Director14 Jan 20197 yrs 10 moSaroja Pharma Industries India Limited
Manish Dasharath Kamble
DIN 08330224
Whole-time director14 Jan 20197 yrs 10 moSaroja Pharma Industries India Limited
Pulinattu Nandakumar
DIN 09852465
Director02 Feb 20233 yrs 9 moSaroja Pharma Industries India Limited
Pinky Kataruka
DIN 08139054
Director05 May 20233 yrs 6 moSaroja Pharma Industries India Limited
Sonal Jain
DIN 10153892
Director09 May 20233 yrs 6 moSaroja Pharma Industries India Limited
Anita Sethia
DIN 08956503
Director03 Sep 20251 yr 2 moSaroja Pharma Industries India Limited
Santosh Shivram Palav
DIN 00349518
Additional Director09 Oct 20251 yr 1 moSaroja Pharma Industries India Limited
Ravindra Shivaji Salaskar
DIN 11315910
Whole-time director09 Oct 20251 yr 1 moSaroja Pharma Industries India Limited

IPO & Listings of Saroja Pharma

Saroja Pharma is a publicly listed company on the NSE with ticker symbol SAROJA in India, operating in the Distribution services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date13 Sep 2023
  • Listed onNSE: SAROJA
  • Listed entitySaroja Pharma Industries India Ltd.
  • Exchange sectorDistribution services
  • ISININE0PCL01011
  • Share price₹40.80 (+4.88% on the day) · 2026-09-30
  • Market capitalisation₹16.4 Cr
  • Price to earnings10.2
  • EPS (diluted, trailing year)₹4.02
  • Volume (last session)1,600

Financials of Saroja Pharma

Exchange-reported figures of Saroja Pharma Industries India Limited, the listed company behind Saroja Pharma (NSE: SAROJA-SM).

Financial Highlights

FY 2025-26 Β· Standalone
Revenue
₹70.13 Cr
+30.5% YoY
EBITDA
₹3.73 Cr
+33.7% YoY
Profit After Tax
₹1.68 Cr
+61.5% YoY
Net Worth
₹17.29 Cr
+10.3% YoY
Total Assets
₹31.70 Cr
+26.1% YoY
Total Debt
₹14.41 Cr
+52.3% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue70.1353.7340.6750.1955.6336.66
Revenue growth+30.5%+32.1%-19.0%-9.8%+51.8%-
EBITDA3.732.792.572.722.091.31
EBITDA margin+5.3%+5.2%+6.3%+5.4%+3.8%+3.6%
Profit before tax2.241.461.221.491.561.05
Net profit1.681.040.891.061.120.75
Net profit margin+2.4%+1.9%+2.2%+2.1%+2.0%+2.1%
EPS (β‚Ή)4.022.572.183.6150.49731.30
Balance sheet
Total assets31.7025.1320.3815.2810.163.95
Net worth17.2915.6814.645.094.030.94
Total debt14.419.465.7310.186.143.02
Cash & bank0.340.330.320.360.260.00
Net working capital8.5112.8111.4310.109.753.83
Cash flow
Cash from operations7.441.151.022.19(3.67)(1.05)
Cash from investing(11.68)(2.70)(4.76)(4.82)(0.34)(0.05)
Cash from financing4.251.563.702.734.271.03

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 18 Nov 2026
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue70.1353.7340.6750.1955.6336.66
Revenue growth+30.5%+32.1%-19.0%-9.8%+51.8%-
Other income0.110.190.190.160.320.09
Total expenses66.4050.9438.1047.4753.5435.35
Employee cost0.690.740.920.830.730.55
EBITDA3.732.792.572.722.091.31
EBITDA margin+5.3%+5.2%+6.3%+5.4%+3.8%+3.6%
Depreciation0.110.110.090.070.050.02
Interest1.491.411.451.320.800.33
Profit before tax2.241.461.221.491.561.05
Tax0.620.420.330.430.440.30
Net profit1.681.040.891.061.120.75
Net profit margin+2.4%+1.9%+2.2%+2.1%+2.0%+2.1%
EPS (β‚Ή)4.022.572.183.6150.49731.30
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital4.024.024.022.940.230.01
Reserves & surplus13.2711.6610.622.153.800.93
Shareholders' funds (net worth)17.2915.6814.645.094.030.94
Secured loans6.108.483.798.005.131.60
Unsecured loans8.310.981.942.181.011.42
Total debt14.419.465.7310.186.143.02
Total liabilities31.7025.1320.3815.2810.163.95
Assets
Gross block2.902.842.742.360.420.12
Net block2.182.502.512.220.350.09
Capital work in progress20.348.616.131.790.000.00
Investments0.540.340.200.140.040.00
Inventories0.860.100.403.870.470.66
Sundry debtors17.3026.5816.2411.1113.987.22
Cash & bank balances0.340.330.320.360.260.00
Loans & advances0.060.210.640.810.380.22
Total current assets18.5627.2217.6016.1515.098.10
Total current liabilities10.0514.416.176.055.344.27
Net working capital8.5112.8111.4310.109.753.83
Total assets31.7025.1320.3815.2810.163.95
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash0.330.320.360.260.000.08
Net cash from operating activities7.441.151.022.19(3.67)(1.05)
Net cash from investing activities(11.68)(2.70)(4.76)(4.82)(0.34)(0.05)
Net cash from financing activities4.251.563.702.734.271.03
Net change in cash0.010.01(0.04)0.100.26(0.07)
Closing cash0.340.330.320.360.260.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth+30.5%+32.1%-19.0%-9.8%+51.8%-
EBITDA growth+33.7%+8.6%-5.5%+30.1%+59.5%-
PBT growth+53.4%+19.7%-18.1%-4.5%+48.6%+9997.0%
Net income growth+61.5%+16.9%-16.0%-5.4%+49.3%-
Revenue CAGR (3Y)+11.8%-1.2%+3.5%---
EBITDA CAGR (3Y)+11.1%+10.1%+25.2%---
Profitability & leverage
Net income margin+2.3%+1.9%+2.2%+2.1%+2.0%+2.1%
Return on capital employed+13.1%+12.6%+14.9%+22.1%+33.7%+34.3%
Return on net worth+9.8%+6.8%+8.9%+23.3%+45.9%+77.7%
Debt / equity0.720.500.811.791.843.21
Long-term debt / equity0.270.130.280.490.631.51
Interest cover41.1652.6158.4749.8139.2225.58
Efficiency & per share
Fixed asset turnover24.4419.2615.9536.11206.04305.50
Inventory turnover146.10214.9219.0523.1398.4655.55
Debtors turnover3.202.512.974.005.255.08
EPS (β‚Ή)4.022.572.183.6150.49731.30
Dividend per share (β‚Ή)0.000.000.000.000.000.00
Book value per share (β‚Ή)43.0038.9936.4217.33178.30935.90

Competitors of Saroja Pharma

Saroja Pharma has 3 listed competitors in our database. They include Del Trade, Globofarm International and HUFORT HEALTHCARE.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
deltrade.in2010Delhi, India76
Serves as a distributor of a wide range of pharmaceutical drugs.
globofarm.net2014Mumbai, India
Manufactures and supplies pharmaceutical ingredients and wellness products worldwide.
hufort.in2007Mumbai, India6
Distributes pharmaceutical raw materials through import, stock, and sales services.
Premium access

Detailed competitors of Saroja Pharma

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Saroja Pharma

Premium access

Complete news archive for Saroja Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Saroja Pharma

Saroja Pharma was founded in 2019.

Saroja Pharma is headquartered in India.

The primary company behind Saroja Pharma, Saroja Pharma Industries India Limited, reported revenue of β‚Ή70.24 Cr for FY 2026, up 31% year on year.

Saroja Pharma Industries India Ltd was founded in 2019 in India. Specialty chemicals, including pharmaceutical ingredients, are traded, exported, and supplied by the company. A range of products is provided to meet industry needs. Operations emphasize ethical practices, equal opportunity, and a harassment-free workplace. Corporate governance is upheld through transparency and accountability in all dealings.

Saroja Pharma's top competitors include Del Trade, Globofarm International and HUFORT HEALTHCARE.

Saroja Pharma offers Specialty Chemicals, Pharma API, and Pharma Intermediates.

Yes, Saroja Pharma is publicly traded on NSE under the ticker symbol SAROJA.

Saroja Pharma operates through Saroja Pharma Industries India Limited.

The legal entities of Saroja Pharma currently have 10 directors, including Anita Sethia, Pulinattu Nandakumar, Yogita Maheshwari and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available